Beloit Memorial Hospital Case Series The Combo of Famotidine & COX-2 Antagonist Cures all 14 COVID-19 Patients

Jul 31, 2020 | Beloit Memorial Hospital, Celecoxib, COVID-19, Famotidine, News, Popular Posts

Beloit Memorial Hospital Case Series The Combo of Famotidine & COX-2 Antagonist Cures all 14 COVID-19 Patients

Two highly respected physicians from Beloit Memorial Hospital in Wisconsin recently uploaded the results of their research for the world to review. A very well respected researcher associated with the U.S. government suggested to the TrialSite to review their work. These physicians articulate that Famotidine, a histamine H2 receptor antagonist/inverse agonist commonly used to treat mast cell activation syndrome (symptoms include anaphylaxis) reduced COVID-19 mortality in one hospital-based retrospective study. The Wisconsin-based providers introduce Prostaglandin E2 (PGE2), a naturally occurring prostaglandin used as a medication, controls various characteristic and adaptive immune responses such as mass cell activation. The providers point out a prospective study involving patients hospitalized for COVID-19 where the administration of the COX-2 antagonist celecoxib not only inhibited PGE2 levels but also prevented clinical degradation and was also connected with improved CT-chest improvement. Hence the Beloit Memorial Hospital providers put forth their hypothesis: adjuvant therapy with a combination of celecoxib with famotidine could very well improve outcomes in hospitalized COVID-19 patients.

The Study Methodology

Actually a consecutive case series led at a single center involving 14 COVID-19 hospitalized patients that were treated with high dose of famotidine in combination with celecoxib as adjuvant therapy. The doctors administered oral famotidine (80 mg four times per day—QID) and oral celecoxib (200 mg twice daily (BID) after a 400 mg loading dose. The doctors looked toward key metrics including time to discharge, changes in supplemental oxygen requirements, CT-chest findings, and laboratory changes in peripheral blood lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, lymphocyte levels and D-dimer.


The Beloit Memorial Hospital pair reported that all of the patients in the series survived hospitalized COVID-19 and were discharged without oxygen with a median of 5 days (range 1-14 days). The providers also observed noticeable improvements in supplemental oxygen requirements, ground-glass CT findings, LDH, ferritin, CRP, D-dimer and lymphocyte levels.

Call for Randomized Controlled Trial

The physicians believe the results justify the investment in a randomized controlled trial to investigate the hypothesis that high dose famotidine with celecoxib could possibly prevent clinical deterioration in adult hospitalized COVID-19 patients.

Famotidine & the Cold Spring Laboratory Case Series

In at least one observational study sponsored by Cold Spring Harbor Laboratory, the prominent New York-based laboratory and some well-respected physicians from Northwell Health Cancer Institute conducted a retrospective case series targeting ten (10) non-hospitalized patients with COVID-19. High doses of famotidine were not only well tolerated by led to improved patient-reported outcomes. This study doesn’t provide any clinical evidence but does represent at least some real world data to consider. Note, there is some controversy associated with famotidine and federal dollars invested in a study at Northwell Health. However that wasn’t associated with the Cold Spring or Beloit Memorial Hospital-based activity.

About Beloit Memorial Hospital

Beloit Health System is an independent community health system serving northern Illinois and southern Wisconsin. The health system offers world-class facilities and services to improve the overall health of the communities they serve with cornerstones for quality, engagement, integrity and patient satisfaction.

Lead Research/Investigator

Kevin Tomera, MD 

Joseph Kittah, MD 

Call to Action: Follow up and read the entire case series report. TrialSite has been informed by very knowledgeable resources that these two doctors are on to an important investigation. See the link

Source: SSRN


  1. kevin tomera md

    the series is about to be updated to 22. The updated paper will include Interleukin-6 IL6, glomerular filtration rate (GFR) and neutrophil lymphocyte ratio. Not only are these predictive markers at baseline but important to follow therapy. We also have a better understanding of mechanism of action including not only lymphocytes but also monocyte/macrophage.
    We knew that none of the cohort required renal replacement therapy (RRT) but I do not want to give away the spoiler readers will be surprised by our findings and Acute Kidney Injury (AKI).

  2. Bw

    Why the cryptic comment regarding acute kidney injury? It would be important to know what you mean for people at home potentially taking Pepcid and Celebrex together.

Pin It on Pinterest